spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Betaseron 

 HSMN NewsFeed - 5 Dec 2022
NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 8 Jan 2011
Important Information for Betaseron (interferon beta 1-b) Consumers Regarding Triad Group's Alcohol Prep Products
Biopharmaceuticals Devices Product Recall
 HSMN NewsFeed - 22 Feb 2010
Acorda Therapeutics Announces Adrian L. Rabinowicz Joins as Senior Vice President of Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jun 2009
Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Apr 2009
New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 Sep 2008
Betaseron(R) to Offer the Thinnest Needle in Multiple Sclerosis
Biopharmaceuticals Drug Delivery Neurology
 HSMN NewsFeed - 7 Nov 2007
BRIGHT Results Show Less Pain and Higher Patient Satisfaction with Betaseron(R) than with Rebif(R)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Oct 2007
Bioject Announces Hiring of President and Chief Executive Officer
Devices Drug Delivery Personnel
 HSMN NewsFeed - 24 Sep 2007
Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jul 2007
Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 25 Jul 2007
Cell Therapeutics, Inc. (CTI) Announces Agreement to Acquire SMi; Gains Global Rights to Brostallicin, in a New Class of Cancer Killing Agents
Biopharmaceuticals Mergers & Acquisitions Oncology
 HSMN NewsFeed - 18 Jun 2007
Oculus Innovative Sciences Appoints Vice President of Regulatory Affairs and Quality
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 May 2007
Studies Presented at Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, and High Patient Satisfaction with Betaseron(R)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 1 May 2007
First of Its Kind Data Show: Immediate Treatment of Early MS Patients with Betaseron(R) Significantly Delayed Permanent Disability
Biopharmaceuticals Neurology
 HSMN NewsFeed - 13 Apr 2007
New One-Year Pharmacoeconomic Study Shows AVONEX(R) is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Apr 2007
First Pharmacoeconomic Analysis with Long-Term Data Showed COPAXONE(R) Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Jan 2007
Nektar Appoints Howard W. Robin President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2007
Diamics Appoints Christine A. Meda as President
Devices Diagnostics Personnel
 HSMN NewsFeed - 23 Nov 2006
Betaferon(R) Approved in Australia for Earliest Stages of Multiple Sclerosis
Biopharmaceuticals Regulatory Neurology
 HSMN NewsFeed - 23 Oct 2006
FDA Approves Betaseron(R) for Use After the First Event Suggestive of Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 12 Oct 2006
KaloBios Pharmaceuticals Appoints David W. Pritchard as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Oct 2006
New Pharmacoeconomic Data on TYSABRI(R) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Oct 2006
Long-Term Data Demonstrated Significantly Better Patient Adherence to COPAXONE(R) versus Interferons in Multiple Sclerosis Treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2006
New Data Confirmed Antibodies to COPAXONE(R) do not Impact Its Established and Sustained Long-Term Efficacy in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2006
New Study: AVONEX(R), The Most Prescribed Multiple Sclerosis Treatment Worldwide, Demonstrates Superior Adherence
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Jul 2006
New Autoinjection Device Designed to Work With Betaseron(R) Now Available For Patients With Multiple Sclerosis
Biopharmaceuticals Devices Neurology Drug Delivery
 HSMN NewsFeed - 31 May 2006
COPAXONE(R) Reduced Relapses and Stabilized Disability as Measured by Expanded Disability Status Scale, When Avonex(R) Failed
Biopharmaceuticals Neurology
Return to NewsFeed  

 Additional items found! 21

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 21 additional stories matching:
Betaseron
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.